Humana upgraded to Buy from Hold at Argus

Argus upgraded Humana (HUM) to Buy from Hold with a $550 price target. Argus views reports that Cigna (CI) and Humana have called off merger talks as positive for Humana, which has solid growth opportunities in Medicare Advantage, Medicaid and healthcare services, the analyst tells investors in a research note. The firm saw “multiple” downsides to a mega-merger in the managed-care industry, including significant antitrust issues and disruptions to ongoing business that could have led to market share losses for Humana.